

AXIRON NET SALES, QUARTER TO 30 SEPTEMBER 2015

Acrux (ASX: ACR) today confirmed that Eli Lilly reported global Axiron net sales of US\$41.4 million in its financial results for the quarter ending 30 September 2015, which is 28% growth compared to sales of US\$32.4 million for the previous quarter to 30 June, 2015.

Compared to the quarter ended 30 September 2014 sales increased by 14%.

Axiron net sales for the calendar year to date are shown in the following table:

Q1 2015	Q2 2015	Q3 2015	Total YTD 2015
US\$39.1m	US\$32.4m	US\$41.4m	US\$112.9m

For further information, contact

Michael Kotsanis, CEO and Managing Director: 03 8379 0100

About Acrux

- Acrux is an Australian drug delivery company, developing and commercialising a range of patient-preferred, pharmaceutical products for global markets, using its innovative technology to administer drugs through the skin.
- The Acrux technology, used in marketed products including Axiron[®], Evamist[®] and Lenzetto[®], is based on a fast-drying, small volume, accurately dosed solution, containing penetration enhancers, that when applied topically, deposit drug through the skin for long acting delivery.
- Acrux has three products marketed by licensees in the USA, three products approved in Europe, and further products at earlier stages of development.

For further information on Acrux, visit www.acrux.com.au

